Cellegy ointment gets approvable letter

The FDA given an approval letter to Huntingdon Valley, PA-based Cellegy for its ointment Cellegesic. The company must conduct another trial of Cellegesic in order to demonstrate statistically significant effectiveness. Cellegy interim CEO Richard C. Williams stated that the company had proven the ointment effective. "The FDA reached a different conclusion... We are carefully considering all of our options and will be scheduling a meeting with the FDA." Shares dropped 32 percent this morning to 44 cents.

- see this press release for more

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.